Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing por ...

DUBLIN, July 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2024 second quarter financial results and provide a business and financial update. Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceutica ...

Investors in JAZZ Pharmaceuticals plc (JAZZ) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $70.00 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an ...

"I am delighted to be stepping into the role of CCO and look forward to leading the combined commercial organization as we continue to scale. I am deeply invested in Jazz's mission and purpose to help patients and remain focused on our commitment to deliver sustainable growth and enhanced value as an innovative global biopharmaceutical company," said Ms. Pearce. "I have had the privilege of leading Jazz's Europe and International organization since 2020 and look forward to continuing to partner closely with ...

Jazz Pharmaceuticals (JAZZ) announced that a mid-stage study evaluating the efficacy and safety of its investigational candidate, suvecaltamide (JZP385), in adult patients with essential tremor (ET) did not meet its primary endpoint. The study also failed to achieve statistical significance on the key secondary endpoint of the Clinical Global Impression-Severity scale, which is a measure of the severity of illness compared with placebo at week 12. Jazz's shares lost 4.7% during trading hours on Jun 20, afte ...

Jazz announced that suvecaltamide failed to meet the primary endpoint in the phase 2b trial, but the company is blaming the placebo response: The oxybate franchise is doing well despite the availability of generic Xyrem and the recent launch of Lumryz Jazz Pharmaceuticals earnings reports Jazz Pharmaceuticals earnings reports deliormanli Suvecaltamide fails in the phase 2b trial in patients with essential tremor While not statistically significant, numeric improvements were observed on the primary endpoint ...

While not statistically significant, numeric improvements were observed on the primary endpoint and key secondary endpoint at 30mg versus placebo. The improvement in placebo from baseline to week 12 also exceeded the Company's expectations and was higher than what was observed for placebo in the prior T-CALM trial of suvecaltamide. About the Phase 2b Trial Suvecaltamide (JZP385) is an investigational, highly selective and state-dependent modulator of T-type calcium channels (Cav3). T-type calcium channels p ...

"We are encouraged by the updated results from the pivotal HERIZON-BTC-01 trial demonstrating sustained clinical activity in previously treated patients with advanced HER2-positive BTC. Results from HERIZON- BTC-01 were included in the Biologics License Application (BLA) for zanidatamab, which was granted Priority Review by the FDA earlier this week, as well as in the Marketing Authorization Application for zanidatamab which was recently submitted to the European Medicines Agency," said Rob Iannone, M.D., M ...

Thirteen abstracts, including five late-breaking abstracts, underscore Jazz's ongoing commitment to advancing the understanding and treatment of serious sleep disorders Oral presentation of XYLO study design to assess systolic blood pressure changes in oxybate patients after switching to low-sodium Xywav® DUBLIN, May 30, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that thirteen abstracts, including five late-breaking abstracts, featuring new data from across its sleep medici ...

DUBLIN, May 29, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 6, 2024 Fireside chat at 11:00 a.m. PT / 2:00 p.m. ET / 7:00 p.m. IST Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 Fireside chat at 7:40 a.m. PT / 10:40 a.m. ET / 3:40 p.m. IST Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma compa ...